New information from medical trials of Tregalizumab, formerly known as BT-061, provide insight into its possible effectiveness for addressing multiple immune-mediated diseases – particularly, iritis. Phase II trials https://mediajx.com/story44470/tregalizumab-a-deep-examination-into-bt-061-s-therapeutic-trials